Navigation Links
Trial of new treatment for advanced melanoma shows rapid shrinking of tumors
Date:9/23/2009

Berlin, Germany: Researchers have made significant advances in the treatment of metastatic malignant melanoma one of the most difficult cancers to treat successfully once it has started to spread according to a study to be presented at Europe's largest cancer congress, ECCO 15 ESMO 34 [1], in Berlin on Thursday.

In the phase I extension study, researchers have seen rapid and dramatic shrinking of metastatic tumours in patients treated with a new compound that blocks the activity of the cancer-causing mutation of the BRAF gene, which is implicated in about 50% melanomas and 5% of colorectal cancers. In new results from 31 melanoma patients with the BRAF mutation who were treated with 960mg of PLX4032 twice a day, 64% (14) of the 22 patients who could be evaluated so far met the official criteria for partial response (this involves the diameter of tumours shrinking by at least 30% for at least a month). A further six of the 22 patients also showed a response, but, at the time of the congress presentation, it was too early to say whether the tumours would shrink far enough to meet these criteria.

Dr Paul Chapman, an attending physician on the Melanoma/Sarcoma service at Memorial Sloan-Kettering Cancer Center (New York, USA) and who was one of the leaders of the trial, told a news briefing: "We are very excited about these results. Of the 22 patients we have been able to evaluate so far, 20 have had some objective tumour shrinkage. This is impressive as they all had metastatic disease and most of them had failed several prior therapies. A lot of these patients were pretty sick but many of them had a significant and rapid improvement in the way they function. We've had patients come off oxygen and we've got several patients who have been able to come off narcotic pain medication soon after starting treatment."

The trial is investigating PLX4032 in patients with the BRAF mutation, and results from the first 55 patients were reported at
'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-771-129-6986
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
2. World-first swine-flu vaccine trial reveals one dose provides strong immune response
3. This idea doesnt stink: New tech cuts industrial odors, pollutants
4. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
5. Britains first swine-flu trials under way
6. Extraterrestrial platinum was stirred into the Earth
7. First genetically-engineered malaria vaccine to enter human trials
8. Results from trials of DHA in Alzheimers disease and age-related cognitive decline
9. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
10. Clinical trial shows quadriplegics can operate powered wheelchair with tongue drive system
11. Enzyme doesnt act alone in atrial fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... The use of iodine-125 (125I) in cancer treatment ... dorsal root ganglia are critical for neural transmission ... Tengda Zhang and colleagues from Institute of Radiation ... that 125I could be implanted into rat dorsal ... pain. 125I seeds with different radioactivity (0, 14.8, ...
(Date:7/30/2014)... analysis of the roughly 3,000 pieces is still in ... the results will be of major significance. "Amazingly often, ... species in Fushun amber that we found in Baltic ... , The Baltic amber comes from the Baltic Sea ... rich in finds are, e.g., the coastal regions of ...
(Date:7/30/2014)... journal Scientific Reports , published by Nature ... that while global temperature is indeed increasing, so too ... each year,s average hottest and coldest temperatures will likely ... a wider range of potential high and low temperate ... even as overall temperatures rise, we may still continue ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2Big data confirms climate extremes are here to stay 2
... LONDON , April 27, 2010 Dominio Amigo S.A.S ... the .CO domain name launch. , , ... Julio Camacho , CEO, Dominio Amigo S.A.S , ... have consistently performed,at both ccTLD and gTLD launches, securing the very best Internet ...
... LONDON , April 27, 2010 ... backdrop. In,a video interview with online financial broadcaster http://www.cantos.com ,Chief Executive ... which,demonstrates the resilience of our business and the success of our enhanced,focus ... ...
... , April 27 The PMI Group, Inc. (NYSE: ... sell in concurrent underwritten public offerings an aggregate of 77,765,000 shares ... $6.15 per share and $261 million aggregate ... connection with the offerings, PMI has granted the underwriters 30-day options ...
Cached Biology News:Dominio Amigo Announce Domainmonster as .CO Technical Partner 2Dominio Amigo Announce Domainmonster as .CO Technical Partner 3Imperial Tobacco - 2010 Half Year Results Interviews 2The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings 2The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings 3The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings 4
(Date:7/30/2014)... 30, 2014 NCERC at Southern ... present his findings on corn stover pretreatment methods ... week in Washington, D.C. , “Arun’s selection ... is a testament to the success of our ... “Thanks to the foresight and vision of SIUE ...
(Date:7/30/2014)... LayerBio, Inc., an MIT spinoff developing ... round of seed financing from friends and family investors. ... develop a novel sustained-release product for ophthalmology. , "We ... their commitment to this important work," said Dr. Ken ... of many areas in which innovations in drug delivery ...
(Date:7/29/2014)...   Sequenom, Inc. (NASDAQ: SQNM ... analysis solutions, and Mayo Medical Laboratories (MML), ... the United States , have announced a ... "We have great appreciation for Mayo Clinic,s ... welcome the opportunity to partner with the organization,s leading ...
(Date:7/29/2014)... ELLICOTT CITY, Md. , July 29, 2014 ... has announced a new and updated program for ... October 10 – 12, 2014 in Amelia ... sponsors, CROs, sites and investigators remains unchanged, however, ... more purposeful exchange and networking opportunity among all ...
Breaking Biology Technology:NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3
... Management to discuss positive corporate developments and ... call, SANTA CLARA, Calif., Oct. 14 ... cardiac diagnostic and services company, today,announced that ... discuss,recent corporate developments and provide an update ...
... release date, NATICK, Mass., Oct. 14 ... the following comments reinforcing,the strength of its balance ... and the Company,s stock price,volatility have had no ... performance of the Company. Strong cash flow generation,during ...
... China, Oct. 14 /Xinhua-PRNewswire/ -- WuXi PharmaTech,(Cayman) ... pharmaceutical, biotechnology and,medical device research and development ... United States, today announced preliminary selected,unaudited financial ... 30, 2008,and updated its guidance for the ...
Cached Biology Technology:NewCardio Management to Host Conference Call on October 21 2NewCardio Management to Host Conference Call on October 21 3Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet 2Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet 3WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 2WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 3WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 4WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 5WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 6WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 7WuXi PharmaTech Announces Preliminary Third Quarter 2008 Results and Updates 2008 Guidance 8
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Rice microRNA Microarray contains all known ...
... is the research-grade spectrofluorometer with a minimum ... S/N ratio 200 or greater for the ... especially designed to keep in mind in ... kinetics, stopped-flow, titration, or anisotropic measurements. ,The ...
... Microarrays designed for genome-wide microRNA ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive microRNA ... Content The Fishes microRNA Microarray ...
Biology Products: